Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) (1).
An open-label, multicenter, randomized, phase III treatment trial to compare ensartinib with crizotinib among 290 enrolled patients with advanced Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) who had not received prior treatment …